High prevalence of thromoembolic complications in heart transplant recipients. Which preventive strategy.?

Transplantation
R ForratM De Lorgeril

Abstract

Consecutive patients transplanted between January 1984 and December 1988 were followed until August 1992 to detect fatal and nonfatal thromboembolic complications, including sudden death, acute and chronic myocardial infarction, pulmonary and peripheral embolisms, stroke, and thrombophlebitis. The probability of developing such complications was 9.86 per 100 patients per year. The probability of fatal complications was 3.97% per year; the mean interval between transplant and death was 1247 days versus 29.5 days for nonthromboembolic deaths. Thromboembolic deaths represented 5.1% of total mortality at the first year posttransplant but 57, 30, 67 and 73% at the second, third, fourth, and fifth years, respectively. Among the prognosis factors that were analyzed, none was significant predictor of thromboembolic complication. This high prevalence of thromboembolic complications suggests that effective antithrombotic strategy should be defined in heart transplant recipients.

References

Feb 1, 1992·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·M de LorgerilS Renaud
Sep 15, 1991·The American Journal of Cardiology·Y ChancerelleJ F Kergonou
Nov 1, 1990·Circulation·S G Young
Jul 19, 1990·The New England Journal of Medicine·P SmithI Holme
Nov 15, 1989·The American Journal of Cardiology·S Z GaoE B Stinson
May 3, 1984·The New England Journal of Medicine·M J Davies, A Thomas
Jun 1, 1994·Chemico-biological Interactions·M de LorgerilA Favier

❮ Previous
Next ❯

Citations

Nov 30, 1999·The International Journal of Angiology : Official Publication of the International College of Angiology, Inc·R R DaviesR J Gusberg
Aug 19, 1999·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·T M SartoriG Antonio
Aug 12, 2000·Acta Anaesthesiologica Scandinavica·H J Toivonen
Aug 13, 1998·Journal of Cardiovascular Pharmacology·M de LorgerilP Boissonnat
Sep 24, 2005·Transplantation·Santiago G MiriukaDavid E C Cole
Dec 23, 2004·Transplant International : Official Journal of the European Society for Organ Transplantation·Santiago G MiriukaDavid E C Cole
Jun 1, 1997·Expert Opinion on Investigational Drugs·J FareedJ M Walenga
Aug 15, 2001·Chest·R LennerG J Schilero
Sep 16, 2004·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Chavit ChantranuwatMichael C Fishbein
Jan 13, 2015·Transplantation Reviews·Berta Sáez-GiménezAntonio Roman
Sep 7, 2016·Progress in Transplantation : Official Publication, North American Transplant Coordinators Organization ... [et Al.]·Alicia B LichvarMichael A Shullo
Mar 17, 2001·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·A RiberiD Metras
Aug 13, 2017·Transplant International : Official Journal of the European Society for Organ Transplantation·Berta Sáez-GiménezAntonio Roman
Aug 29, 2018·ASAIO Journal : a Peer-reviewed Journal of the American Society for Artificial Internal Organs·Jeremy MoretzSandip Zalawadiya

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.